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We report six of 16 U.K. melanoma families and two of
17 patients with multiple primary melanomas and a
negative family history who have between them four
different functionally damaging mutations of the
CDKN2A (p16) gene: an Arg 24 Pro substitution in exon
1 in one family, a stop codon at codon 44 of exon 1 in
one family, and a Met 53 Ile substitution in exon 2 in
four families. One multiple primary melanoma patient
Genetic linkage analysis has shown that a proportionof patients with both familial and sporadic cutaneousmelanoma show loss of heterozygosity on chromo-some 9p21 (Cannon-Albright et al, 1992, 1994).Studies of familial melanoma patients in the U.S.A.
(Hussussian et al, 1994; Kamb et al, 1994; Fitzgerald et al, 1996),
Australia (Walker et al, 1995; Holland et al, 1995), The Netherlands
(Gruis et al, 1995) Sweden (Borg et al, 1996; Platz et al, 1997),
England (Harland et al, 1997), and France (Soufir et al, 1998) have
detected mutations of the CDKN2A gene (also known as p16 or
MTS1 gene) in approximately one-sixth of cases of familial
melanoma. CDKN2A is a small gene consisting of three exons and
is situated on chromosome 9p21. The normal function of CDKN2A
is to encode the CDKN2A protein that inhibits the cyclin dependent
kinases CDK4 and CDK6. These kinases are responsible for
controlling the passage of cells through the G1 checkpoint by
inhibiting the phosphorylation of the retinoblastoma protein (Serrano
et al, 1995). Wild-type CDKN2A is therefore regarded as a tumor
suppressor gene, and mutations have been detected in a wide range
of human malignancies, including melanoma (Foulkes et al, 1997).
We report results of screening 16 families drawn from a population
based melanoma register in the U.K. We have identified three
distinct CDKN2A mutations in six families, and two mutations in
17 patients with multiple primary melanomas and no evidence of
a family history of melanoma.
MATERIALS AND METHODS
Patients Melanoma patients were identified through the records of the
Scottish Melanoma Group, a population based registry of all patients in
whom invasive cutaneous melanoma is diagnosed in Scotland. At present
there are over 8000 melanoma patients registered (MacKie et al, 1997), and
the families identified for this study were selected on the basis of being
located in the west of Scotland and being willing to attend together with
unaffected family members who would all undergo full skin examination
and donate a blood sample for DNA extraction. All patients had at least
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also has the Met 53 Ile mutation and a second has a G-T
substitution at the IVS2 1 1 splice donor site. Our data
together with other recent publications from France and
the U.S.A. indicate that screening melanoma kindreds
with only two affected family members for CDKN2A
mutations is justified. Key words: familial melanoma/growth
suppressor/p16/tumor suppressor. J Invest Dermatol 111:269–
272, 1998
one other living family member with pathologically confirmed invasive
melanoma who also donated DNA.
Details of the families are shown in Table I and the family trees of
those with mutations detected are shown in Fig 1. The largest family, mel
2, has to date four family members with invasive melanoma and the index
case in this family has to date four distinct primary cutaneous melanomas.
His brother, sister, and son all have one invasive primary melanoma, and
his second son who also carries the mutation has a medium sized congenital
naevus on the dorsum of his right foot. One other family has three affected
members in three generations and the remaining four all have two affected
family members.
The 17 patients screened with multiple primary melanomas are representative
with regard to sex distribution, age at presentation, and thickness of first
primary melanoma of a series of 108 patients with multiple invasive primary
melanomas in which we have investigated risk factors and prognostic factors
in individuals who have multiple primary melanomas Burden et al, 1994).
The 17 who gave DNA for this study comprised eight males and nine
females with a mean age at presentation with first primary of 49 y (range
22–70 y). Fourteen had two invasive primary melanomas, two had three,
and one had eight primary melanomas. These patients do not have other
nonmelanoma malignancies.
Design and synthesis of oligonucleotide primers The polymerase chain
reaction primer sequences used to amplify exons 1 and 2 of CDNK2A
were designed with the aid of the OLIGO Version 3.4 program (Wojciech
Rychlik; MEDPROBE). The sequences of the primers for exon 3 were
identified from Kamb et al (1994) and synthesized.
The polymerase chain reaction and single stranded conformational
polymorphism analysis Standard conditions were used for polymerase
chain reactions. For single stranded conformational polymorphism analysis
(Orita et al, 1989), 4 µl polymerase chain reaction product was mixed with
6 µl of single stranded conformational polymorphism loading buffer. Samples
were denatured at 95°C for 5 min then chilled on ice and 4 µl loaded per
well. Products were resolved by running in 0.5% mutation detection
enhancement gels (Flowgen, Lichfield, Staffs, U.K.) and 5% glycerol at 4 W
for 16 h at room temperature. The DNA bands were visualized by silver
staining then photographed.
DNA sequencing Double stranded polymerase chain reactions were carried
out on the relevant DNA, and the DNA products purified by ethanol
precipitation and dissolved in 20 µl of sterile double distilled water.
Sequencing reactions were then carried out using the Thermo Sequenase
Dye Terminator Cycle sequencing premix kit (Amersham, Essex, U.K.)
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Table I. Details of 16 U.K. melanoma families screened for germline mutations of the CDKN2A genea
Case no. Index case and age at diagnosis of first primary Affected relatives Mutation detected
1 Female (39) Mother and grandmother Exon 2 Met 53 Ile
(2 primary melanomas)
2 Male (31)
(4 primary melanomas) Brother, sister, and son Exon 1 Arg 24 Pro
3 Female (33) Mother (55) Exon 1 tyr 44 stop
(2 primary melanomas)
4 Male (46) Sister (46) Exon 2 Met 53 Ile
(2 primary melanomas) (3 primaries)
5 Female (27) Cousin (36) Exon 2 Met 53 Ile
(2 primary melanomas)
6 Female (34) Daughter (21) Exon 2 Met 53 Ile
7 Female (45) Brother (43) –
8 Female (41) Sister (23) –
9 Male (21) Mother (56) –
10 Male (53) Sister (45) –
11 Male (63) Daughter (32) –
12 Female (37) Father (69) 500 G/C
13 Male (34) Brother (36) –
14 Female (31) Mother (68) –
15 Female (61) Son (48) –
16 Female (16) Father –
Patients with multiple primary melanomas and CDKN2A mutations
Male (28) 8 primaries (4 synchronous) Exon 2 Met 53 Ile
Female (29) 2 primaries (synchronous) IVS2 1 1 G . T
aAll melanomas included in this table are invasive, i.e., level 2 or deeper.
using standard protocols for the ABI 373 sequencer. Data are presented in
chromatogram form where C 5 blue, A 5 green, T 5 red, and G 5
black. Heterozygosity is generally represented by two superimposed peaks
and designated N (Fig 2).
RESULTS
All three exons of the CDKN2A gene were scanned by single
stranded conformational polymorphism analysis for mutations, and
all variant bands subsequently analyzed by direct sequencing to
confirm the presence of a mutation. Three distinct mutations were
detected in six of the 16 families screened, and a seventh family
had a previously recognized polymorphism (Chaubert et al, 1996).
We did not detect any CDKN2A abnormality in the remaining
nine families.
The three mutations detected were a substitution of proline for
arginine in codon 24 of exon 2 in the largest family studied, which
to date has four affected family members (UKFM 2), a stop codon
at 44 in exon 1 in a mother and daughter (UKFM 3), and an
isoleucine substitution for methionine at codon 53 of exon 2 in
four other families comprising a brother and sister, two cousins,
and two mothers and daughters (UKFM 1, 4, 5, and 6) The one
family that showed the 500 G/C polymorphism consisted of a
father and daughter (UKFM 12).
Two of the 17 patients with multiple primary melanomas and a
negative family history had CDKN2A mutations. One, a male who
has to date developed eight separate invasive primary melanomas
and who has no detectable defect in DNA repair, has the exon 2
Met 53 Ile mutation. The second is a female who had two
synchronous primary melanomas excised 12 y ago and has a G-T
substitution at the IVS2 1 1 splice donor site. As G is the first
base of the intron this will affect splicing as the first two bases
always have a consensus sequence GT. Seven of the other patients
screened with multiple primary melanomas showed the G-C
polymorphism 29 bp downstream of the coding region of exon 3, and
the remaining eight showed neither mutations nor polymorphisms.
All of the mutations detected in this series of patients are likely
to be functionally deleterious. The G47 to C transversion in codon
24 (CGG to CCG) in family UKFM 2 is a missense mutation that
changes the basic amino acid arginine to proline (Arg24Pro), which
is neutral and hydrophobic and would therefore be expected to
have both a structural and a functional effect on the protein.
Harland et al has recently shown that this variant is defective in
binding to CDK4 but normal in binding to CDK6, and in addition
has shown no CDK binding for the Met 53 Ile mutation (Harland
et al, 1997). As a premature termination codon, the tyr 44 stop
codon in exon 1 seen in family UKFM 3 is highly likely to be
functionally deleterious.
DISCUSSION
To date, studies on melanoma families worldwide suggest that the
presence and frequency of CDKN2A mutations in familial melanoma
varies between continents, and also between patient groups in the
same continent. For example, Hussussian et al (1994) reported on
13 of 18 families from the U.S.A. with CDKN2A mutations (72%),
whereas Kamb et al (1994), also in the U.S.A., found mutations in
only two of 36 families; however, the US study most relevant to
this study is that of Fitzgerald et al (1996), who report five
CDKN2A mutations in 33 patients from 28 families in a clinic
based population. It is of importance that these families were
defined, as were ours, as having only one affected first degree
family member, a population much commoner than the larger
cancer families studied by family cancer geneticists. The recently
published french study of 48 families (Soufir et al, 1998) further
emphasizes the fact that CDKN2A mutations are found in kindreds
with only two affected family members (eight of 28 or 28%) as
well as in kindreds with larger numbers of affected members. In
other parts of Europe, CDKN2A mutations have been recorded in
a large Dutch kindred (Gruis et al, 1995) and in two of 10 and
five of 64 Swedish families, respectively (Borg et al, 1996; Platz
et al, 1997), and in six of 27 U.K. families (MacGeoch et al, 1994;
Harland et al, 1997). In Australia, Walker et al (1995) found
CDKN2A mutations in seven of 18 Australian melanoma pedigrees
(39%), whereas a second Australian study (Holland et al, 1995)
showed only one of 17 melanoma families to express CDKN2A
mutations. The Met 53Ile substitution found in four of our families
was first reported by Walker et al (1995), and results from a G-C
substitution at codon 153, and was found by Walker to segregate
with the putative melanoma chromosome in a large Australian
kindred. They stated that this Australian family ‘‘probably originated
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Figure 1. Family trees of the six families in which CDKN2A mutations
were detected. Filled squares and circles indicate males and females with
invasive melanoma, and figures adjacent to these symbols indicate age at
diagnosis of first invasive primary melanoma. A plus sign indicates the presence
of a mutation detected by sequencing. In families UKFM 1, 4, 5, and 6 this is
the Met 53 Ile mutation in exon 2, in UKFM 2 this is Arg 24 Pro in exon 1,
and in UKFM 3 this is a stop codon at codon 44 of exon 1.
from Scotland.’’ Collaborative studies are currently in progress
between ourselves and the Australian group to establish whether or
not the families share common ancestry.
The tyr 44 stop codon in exon 1 of CDKN2 has previously
been reported in non-small cell lung cancer (Washimi et al, 1995)
but this appears to be the first report of this particular mutation in
melanoma.
In our family UKFM 2 it appears that in generation 2 among
the five siblings, the CDKN2A mutation segregates with the disease,
and surveillance continues of the two children in generation 3 who
have the mutation but not as yet melanoma. One of these children
has an intermediate sized congenital naevus. Congenital naevi have
to date not been reported in patients with CDKN2A mutations,
Figure 2. Chromatograms showing the mutations detected. (a) The Met
53 Ile substitution detected in families mel 1, 4, 5, and 6; (b) the normal
chromatogram picture for the relevant section of the gene. (c) The G-C
polymorphism at base 500 of the three prime untranslated region of exon 3,
and (d) the more commonly seen pattern in this area. In all chromatograms the
relevant area is marked with an asterisk.
and there is controversy about their malignant potential. In other
reports, clear segregation of melanoma with the gene mutation is
not invariably the case, although in other pedigrees there appears
in some cases to be linkage to chromosome 9, but no CDKN2A
mutation. This could be due to another as yet unidentified suppressor
gene in this area of chromosome 9, or to inappropriate assignment
to 9p21, based on a weak LOD score.
The genetics of patients with multiple primary melanomas but
no family history have not as yet been reported in detail. Brill et al
(1997) reports five of 34 patients with two or more primary
melanomas with CDKN2A mutations, but subsequently found two
of the five to have a positive family history. They conclude that
the presence of such mutations may indicate an occult family history
of melanoma. Harland et al (1997) record no mutations in three
patients studied with multiple primary melanomas. Our sample of
17 patients with multiple primary melanomas, two of whom have
CDKN2A mutations, indicates that this group of patients merits
further study.
In conclusion, this study has added six new families to the known
population of families with melanoma and CDKN2A mutations.
Our data together with that of Fitzgerald and Soufir suggest that
investigating families with only two affected members is worthwhile.
Such families will be found in the care of dermatologists, oncologists,
or surgeons and family cancer services may well not be notified.
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In future, knowledge of CDKN2A status may well be relevant to
melanoma screening, surveillance, or early detection activities
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